Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 9/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5343949 | 0.91 | NOS2 (0.47) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| Fumaric Acid SCHEMBL5343944 | 0.91 | NOS2 (0.47) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5354753 | 0.78 | SLC6A4 (0.52) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5348140 | 0.78 | SLC6A4 (0.52) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5353457 | 0.77 | SLC6A4 (0.57) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5339349 | 0.77 | SLC6A4 (0.51) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5346128 | 0.76 | SLC6A4 (0.50) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5344013 | 0.76 | SLC6A4 (0.61) | SLC6A4KCNH2SLC6A2SLC6A3HTR2A | |
| SCHEMBL5344036 | 0.76 | SLC6A4 (0.60) | SLC6A4KCNH2SLC6A2SLC6A3HTR2A | |
| SCHEMBL5348203 | 0.75 | SLC6A4 (0.49) | SLC6A4KCNH2SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119122-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | claimed |
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | claimed |
| EP-1434756-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-07-07 | — | — | EP | claimed |
| WO-2003029185-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | WO | claimed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| US-7276528-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7119122-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20060217424-A1 | Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain | CONNOLLY STEPHEN | 2006-09-28 | — | — | US | disclosed |
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | disclosed |
| EP-1434756-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003029185-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | NOS2, NOS1, NOS3 | SLC6A4 1294/4885KCNH2 4270/4885SLC6A2 1006/4885 |
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | NOS1, NOS3, NOS2 | SLC6A4 395/4885KCNH2 852/4885SLC6A2 870/4885 |
| US-20060217424-A1 | Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain | NOS3, NOS1, NOS2 | SLC6A4 1110/4885KCNH2 424/4885SLC6A2 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.